๐ ็ธฝ็ฎ้ ๏ฝ ๐ ่ฑๆๅๆ๏ผๆฌ็ฏ๏ผ ๏ฝ ๐ ๅฎๆด็ฟป่ญฏ ๏ฝ โญ ็ฒพ่ฏ็ญ่จ
INTRODUCTION
The term cutaneous T cell lymphoma (CTCL) describes a heterogeneous group of neoplasms of skin-homing T cells that show considerable variation in clinical presentation, histologic appearance, immunophenotype, and prognosis. CTCLs represent ~75%โ80% of all primary cutaneous lymphomas, whereas primary cutaneous B cell lymphomas (CBCLs) account for ~20%โ25%. For many years, mycosis fungoides (MF) and Sรฉzary syndrome (SS) were the only known types of CTCL. Over the past three decades, based on a combination of clinical, histologic and immunophenotypic criteria, new types of CTCL and CBCL have been defined and new classifications for the group of primary cutaneous lymphomas have been formulated1โ3,3a,3b. A major advantage in the management of primary cutaneous lymphomas compared with lymphomas arising at other sites is that the former can be seen and can be biopsied easily, giving the dermatologist the unique opportunity to correlate the clinical appearance and clinical behavior with histologic, immunophenotypic, and genetic aspects of these conditions. Hence, the dermatologist can play a key role in the diagnosis, classification, and treatment of these diseases.